---
title: "Prevalence of protective anti-HBs among women delivering at Kawempe National Referral Hospital, Ug"
id: "medrxiv-18-prevalence-of-protective-hepatitis-b-surface-antibody-levels-and-associated"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-18-prevalence-of-protective-hepatitis-b-surface-antibody-levels-and-associated"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.10.26367773v1?rss=1"
published_at: "2026-11-12T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Prevalence of protective anti-HBs among women delivering at Kawempe National Referral Hospital, Ug
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-18-prevalence-of-protective-hepatitis-b-surface-antibody-levels-and-associated
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.10.26367773v1?rss=1)
- **Published At:** 2026-11-12T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators conducted a cross-sectional survey of 418 women admitted for delivery at Kawempe National Referral Hospital in 2024; participants were selected by systematic random sampling and interviewed about exposures, testing and **vaccination**. - The study team quantified **anti-HBs** by electrochemiluminescence immunoassay; protection was defined as ≥10 mIU/mL, while other HBV markers were screened using a rapid test. - Overall seroprotection (anti-HBs ≥10 mIU/mL) was found in 322 women (77.0%; 95% CI 72.8–80.8). - Protection varied by vaccination history: 50.6% of never-vaccinated women had protective levels, 82.0% of those vaccinated before the current pregnancy only, and 95.6% of women vaccinated during the current pregnancy. - The cohort reported 264 women (63.2%) had received at least one dose of vaccine; 203 vaccinated during current pregnancy, 61 before it only. - Modified Poisson regression indicated vaccination before the current pregnancy only (adjusted prevalence ratio 1.54; 95% CI 1.24–1.89) and vaccination during pregnancy (aPR 1.86; 95% CI 1.57–2.20) were associated with protective **anti-HBs** levels; no socio-demographic or behavioural factors remained associated after adjustment. - Rapid screening detected HBsAg in 21 women (5.0%), but the authors noted discordant marker patterns that suggest some false positives. - The study identified programmatic gaps: 82 women (19.6%) had no serological evidence of immunity or infection at delivery; 65 of these had never been vaccinated. Among vaccinated women with known completion status, 68 of 250 (27.2%) had not completed three doses, commonly because they were not advised to return or they forgot. - The authors observed that negative antenatal tests did not consistently lead to vaccination; they concluded that linking every negative antenatal test to a vaccination offer could reduce the proportion of susceptible women at delivery. - The preprint reports ethical approvals and informed consent; vaccination was not provided as part of the study and infected women were to be referred for clinical care.
## Clinical Analysis & Structured Key Points
Prevalence of protective hepatitis B surface antibody levels and associated factors among women admitted for delivery at Kawempe National Referral Hospital, Uganda: A cross-sectional study | medRxiv Skip to main content Prevalence of protective hepatitis B surface antibody levels and associated factors among women admitted for delivery at Kawempe National Referral Hospital, Uganda: A cross-sectional study View ORCID Profile EMILLY KEMBABAZI , MOSES OCAN , HOOD IBANDA doi: https://doi.org/10.64898/2026.11.10.26367773 EMILLY KEMBABAZI 1 Makerere University CHS: Makerere University College of Health Sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for EMILLY KEMBABAZI For correspondence: emillykemba{at}gmail.com MOSES OCAN 2 Makerere University Find this author on Google Scholar Find this author on PubMed Search for this author on this site HOOD IBANDA 2 Makerere University Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Data/Code Preview PDF Abstract Mother-to-child transmission sustains the burden of hepatitis B virus (HBV) infection in sub-Saharan Africa, yet little is known about whether women giving birth in Uganda are protected. We estimated the prevalence of protective hepatitis B surface antibody (anti-HBs) levels, described serological profiles and identified associated factors among women admitted for delivery at Kawempe National Referral Hospital, Kampala. In this cross-sectional study, 418 women were selected by systematic random sampling in 2024 and interviewed about socio-demographic characteristics, hepatitis B testing, vaccination and exposures. Anti-HBs was quantified by electrochemiluminescence immunoassay (protective: ≥10 mIU/mL); other HBV markers were screened with a rapid test. Prevalence ratios were estimated with modified Poisson regression. Overall, 264 women (63.2%) reported vaccination: 203 during the current pregnancy and 61 before it only. Protective levels were found in 322 women (77.0%; 95% confidence interval [CI] 72.8–80.8): 50.6% of never-vaccinated women, 82.0% of those vaccinated before the current pregnancy only and 95.6% of those vaccinated during it. After adjustment, vaccination before the current pregnancy only (adjusted prevalence ratio 1.54; 95% CI 1.24–1.89) and during it (1.86; 95% CI 1.57–2.20) were associated with protection; no socio-demographic or behavioural factor was. Eighty-two women (19.6%) had no serological evidence of immunity or infection; 65 had never been vaccinated. Of 300 women who reported a previous negative test, 50 (16.7%) had never been vaccinated, and 68 of 250 vaccinated women with known completion status (27.2%) had not completed three doses, mostly because they were not told to return or forgot. The rapid test detected hepatitis B surface antigen in 21 women (5.0%), but discordant marker patterns suggest some false positives. One in five women reached delivery susceptible to HBV, largely because a negative test was not followed by vaccination. Linking every negative antenatal test to vaccination could close much of this gap. Competing Interest Statement MO chairs the Makerere University School of Biomedical Sciences Research and Ethics Committee, which approved this study he did not take part in the committee?s review of this protocol. The authors have declared that no other competing interests exist. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study protocol was approved by the Makerere University School of Biomedical Sciences Research and Ethics Committee (SBS-REC) at its meeting of 16 November 2023 (reference SBS-2023-452 approval valid from 12 February 2024 to 12 February 2025). MO, who chairs the SBS-REC, did not take part in the committee's review of this protocol. Administrative clearance to conduct the study at KNRH was granted by the Executive Director of the hospital on 17 May 2024 (reference ED.01/04/024). All data were collected after this clearance and within the period of ethics approval. All participants provided written informed consent before enrolment. Under the approved protocol, women found to be infected were to be referred to a physician for further management vaccination was not provided as part of the study. Personal identifiers were replaced with unique study codes, and the data were stored on password-protected computers accessible only to the study team. The study was conducted in accordance with the Declaration of Helsinki. Consent: written informed consent obtained from all participants. Participants were all aged 18 years or older (no minors). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All relevant data are within the manuscript and its Supporting Information files. The de-identified participant-level dataset and codebook are provided as S1 Data.. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted November 12, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Prevalence of protective hepatitis B surface antibody levels and associated factors among women admitted for delivery at Kawempe National Referral Hospital, Uganda: A cross-sectional study Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Prevalence of protective hepatitis B surface antibody levels and associated factors among women admitted for delivery at Kawempe National Referral Hospital, Uganda: A cross-sectional study EMILLY KEMBABAZI , MOSES OCAN , HOOD IBANDA medRxiv 2026.11.10.26367773; doi: https://doi.org/10.64898/2026.11.10.26367773 Share This Article: Copy Citation Tools Prevalence of protective hepatitis B surface antibody levels and associated factors among women admitted for delivery at Kawempe National Referral Hospital, Uganda: A cross-sectional study EMILLY KEMBABAZI , MOSES OCAN , HOOD IBANDA medRxiv 2026.11.10.26367773; doi: https://doi.org/10.64898/2026.11.10.26367773 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (638) Allergy and Immunology (922) Anesthesia (352) Cardiovascular Medicine (5021) Dentistry and Oral Medicine (496) Dermatology (429) Emergency Medicine (680) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1696) Epidemiology (16286) Forensic Medicine (36) Gastroenterology (1243) Genetic and Genomic Medicine (7297) Geriatric Medicine (753) Health Economics (1095) Health Informatics (5305) Health Policy (1475) Health Systems and Quality Improvement (1837) Hematology (599) HIV/AIDS (1383) Infectious Diseases (except HIV/AIDS) (16505) Intensive Care and Critical Care Medicine (1203) Medical Education (701) Medical Ethics (157) Nephrology (754) Neurology (7619) Nursing (380) Nutrition (1133) Obstetrics and Gynecology (1297) Occupational and Environmental Health (1041) Oncology (3752) Ophthalmology (1096) Orthopedics (411) Otolaryngology (468) Pain Medicine (503) Palliative Medicine (143) Pathology (722) Pediatrics (1864) Pharmacology and Therapeutics (757) Primary Care Research (787) Psychiatry and Clinical Psychology (6155) Public and Global Health (10015) Radiology and Imaging (2543) Rehabilitation Medicine and Physical Therapy (1526) Respiratory Medicine (1273) Rheumatology (663) Sexual and Reproductive Health (805) Sports Medicine (599) Surgery (806) Toxicology (109) Transplantation (320) Urology (309)
## Related Clinical Research

- [GSK wins approval for hepatitis B therapy as biotech news ripples through sector](https://medichelpline.com/clinical-feed/stat-news-0-stat-gsk-picks-up-hep-b-drug-approval.md)
- [Immune checkpoint inhibitor–related multi-organ injury with severe pneumonia: case report (Frontie](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-immune-checkpoint-inhibitor-induced-multi-organ-immune-damage-complicated-by.md)
- [Monocyte phenotypes associated with peri‑coronary inflammation in people with and without HIV](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-distinct-monocyte-phenotypes-are-associated-with-peri-coronary-inflammation-in.md)
- [Reflecting on 50 Years of Interleukin-2: Advancements in Immunotherapy and Retrovirology](https://medichelpline.com/clinical-feed/stat-news-2-opinion-50-years-ago-my-colleagues-and-i-pursued-basic-research-science-that.md)
- [State-Level Estimates of Hepatitis C Virus Prevalence in the US, 2017–2020](https://medichelpline.com/clinical-feed/medrxiv-1-estimating-hepatitis-c-virus-prevalence-in-us-states-and-the-district-of.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.